Ezogabine: A novel antiepileptic as adjunctive therapy for partial onset seizures

Drugs of Today

Volumn 46, Issue 11, 2010, Pages 815-822

  Owen, Richard T ^a  

^a Freelance Medical Writer   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; AWD 21360; CYTOCHROME P450; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; EZOGABINE; LAMOTRIGINE; MOXIFLOXACIN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PLACEBO; RETIGABINE; UNCLASSIFIED DRUG; CARBAMIC ACID DERIVATIVE; PHENYLENEDIAMINE DERIVATIVE;

ACETYLATION; ADJUVANT THERAPY; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; ATAXIA; BIOEQUIVALENCE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); CONFUSION; CONVULSION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; FATIGUE; FOCAL EPILEPSY; GENDER; GLUCURONIDATION; HUMAN; IC 50; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEPHROLITHIASIS; NEUROTRANSMISSION; NONHUMAN; QT PROLONGATION; RACE; REVIEW; RISK REDUCTION; SEIZURE; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; URINARY TRACT DISEASE; URINARY TRACT INFECTION; VERTIGO; ANIMAL; DOSE RESPONSE; DRUG INTERACTION; PATHOPHYSIOLOGY; TIME;

ANIMALS; ANTICONVULSANTS; CARBAMATES; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EPILEPSIES, PARTIAL; HUMANS; PHENYLENEDIAMINES; TIME FACTORS;

EID: 79955805815     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.11.1556435     Document Type: Review

References (30)

1. Hirtz, D., Thurman, D.J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A.R., Zalutsky, R. How common are 'common' neurologic disorders? Neurology 2007, 68(5): 326-7.
2. Sander, J.W. The epidemiology of epilepsy. Curr Opin Neurol 2003, 16(2): 165-70.
3. Kwan, P., Brodie, M. Early identification of refractory epilepsy. N Engl J Med 2000, 342(5): 314-9.
4. Elger, C.E., Schmidt, D. Modern management of epilepsy: A practical approach. Epilepsy Behav 2008, 12(4): 501-39.
5. Czuczwar, P., Wojtak, A., Cioczek-Czuczwar, A., Parada-Turska, J., Maciejewski, R., Czuczwar, S. Retigabine: The newer potential antiepileptic drug. Pharmacol Rep 2010, 62(2): 211-9.
6. Rundfeldt, C. The new anticonvulsant retigabine (D-23219) acts as an opener of potassium channels in neuronal cells. Eur J Pharmacol 1997, 336(2-3): 243-9.
7. Advisory Committee Briefing Document. Ezogabine for partial seizures in epilepsy (NDA-022345). http://fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM221682.pdf (Accessed Oct 27, 2010).
8. Tatulian, L., Delmas, P., Abogadie, F.C., Brown, D.A. Activation of expressed KCNQ potassium channels and native neuronal M-type potassium currents by the anticonvulsant drug retigabine. J Neurosci 2001, 21(15): 5535-45.
9. Otto, J.F., Kimball, M.M., Wilcox, K.S. Expression of the anticonvulsant retigabine on cultured cortical neurons: Changes in electroresponsive properties and synaptic transmission. Mol Pharmacol 2002, 61(4): 921-7.
10. Rundfeldt, C., Meltzer, R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary cells transfected with human KCNQ2/3 subunits. Neurosci Lett 2000, 282(1-2): 73-6.
11. van Rijn, C.M., Willems-vanBree, E. Synergy between retigabine and GABA in modulating the anticonvulsant site of the GABA-A receptor complex. Eur J Pharmacol 2003, 464(2-3): 95-100.
12. Kapetanovic, J.M., Yonekawa,W.D., Kupferberg, H.J. The effects of D-23129, a new experimental anticonvulsant drug on neurotransmitter acids in the rat hippocampus in vitro. Epilepsy Res 1995, 22(3): 167-73.
13. Ferron, G.F., Paul, J., Fruncillo, R., Richards, L., Knebel, N., Getsy, J., Troy, S. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002, 42(2): 175-82.
14. Hermann, R., Schneider, E., Menth, M. et al. Progress report on new antiepileptic drugs: A summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002, 51: 36-8.
15. Borlak, J., Gasparic, A., Locher, M., Schupke, H., Hermann, R. N-Glucuronidation of the antiepileptic drug retigabine: Results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney and liver microsomal membranes of the Crigler-Najjar type II. Metab Clin Exp 2006, 55(6): 711-21.
16. Hermann, R., Ferron, G.M., Erb, K. et al. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003, 73(1): 61-70.
17. Hermann, R., Borlak, J., Munzel, U., Niebch, G., Fuhr, U., Maus, J, Erb, K. The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine. Pharmacogenomics 2006, 6(3): 211-9.
18. th Eur Congr Epileptology (Rhodes, June 27-July 1) 2010, Abst 187.
19. Hermann, R., Knebel, N.G., Niebch, G., Richards, L., Borlak, J., Locher, M. Pharmacokinetic interaction between lamotrigine and retigabine in healthy subjects. Eur J Clin Pharmacol 2003, 58(12): 795-802.
20. Ferron, G.M., Patat, A., Parks, V., Rolan, P., Troy, S.M. Lack of pharmacokinetic interaction between retigabine and phenobarbital at steady state in healthy subjects. Br J Clin Pharmacol 2003, 56(1): 39-45.
21. Ferron, G.M., Paul, J., Richards, L., Getsy, J., Troy, S. Retigabine does not alter the pharmacokinetics of a low dose oral contraceptive in women. Neurology 2001, 56(Suppl. 3): Abst P.05.052.
22. Porter, R.J., Patriot, A., Sachdeo, R., Nohria, V., Alves, W.M. Randomized, multicenter, dose-ranging trial of retigabine for partial onset seizures. Neurology 2007, 68(15): 1197-204.
23. French, J., Mansbach, H. Retigabine as adjunctive therapy in adults with refractory partial onset seizures. Epilepsia 2009, 50(Suppl. 4): Abst 089.
24. Lerche, H., Mansbach, H., Shin, P., Hall,S. Long term maintenance of efficacy with retigabine in adult epilepsy patients. Epilepsia 2009, 50(Suppl. 4): Abst 1.238.
25. Brodie, M.J., Lerche, H., Gil-Nahel, A. et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010, 75(20): 1817-24.
26. Mansbach, H., Rosenfeld, W., Shin, P., Hall, S. Long term maintenance of efficacy with retigabine in adult epilepsy patients: Extension study of RESTORE 1. Epilepsia 2009, 50(Suppl. 11): Abst 1.248.
27. Bialer, M., Johannessen, S.I., Levy, R.H., Perucca, E.Tomson, T., White, H.S. Progress report on new antiepileptic drugs: A summary of the Ninth EILAT Conference. Epilepsy Res 2009, 83(1): 1-43.
28. Sperling, M.R. Sudden unexplained death in epilepsy. Epilepsy Curr 2001, 1(1): 21-3.
29. Tomson, T., Walczak, T., Sillanpaa, M., Sander, J.W. Sudden unexplained death in epilepsy: A review of incidence and risk factors. Epilepsia 2005, 46(Suppl. 11): 54-61.
30. Lathers, C.M., Schrader, P.L. Clinical pharmacology: Drugs as a benefit and/or risk in sudden unexplained death in epilepsy? J Clin Pharmacol 2002, 42(2): 123-36.